Subject matter experts from ATCC present at the Association of Molecular Pathology (AMP) conference in Charlotte, North Carolina.
The National Cancer Institute (NCI) awarded ATCC a contract to distribute a new generation of cancer models under the Human Cancer Models Initiative (HCMI).
ATCC and BioAgilytix announce a strategic partnership to develop new and custom cell-based assays to accelerate and enhance biopharmaceutical research and development.
ATCC Wins Multimillion Dollar Contract to Manage and Operate One of the World's Largest Repositories
Leidos Biomedical Research, Inc. (Leidos Biomed) awarded ATCC a two-year base option subcontract to manage and operate one of the largest repositories of biological specimens in the world, in Frederick, Md.
ATCC announces that it has entered into a three-year cooperative research and development agreement (CRADA) with the National Institute of Standards and Technology (NIST) to determine and validate short tandem repeat (STR) markers for mouse cell line authentication.
ATCC is pleased to announce that Dr. Yvonne Reid, ATCC senior scientist, received the Distinguished Lifetime Achievement Award from the Society for In Vitro Biology (SIVB) in recognition of her trailblazing work in Short Tandem Repeat (STR) DNA profiling for human cell line identification.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded ATCC a multimillion dollar recompete contract for its Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) program.
ATCC announces the appointment of Dr. Shou C. Wong as senior director of ATCC Microbiology Systems (AMS).
ATCC announces the appointment of Dr. Mindy Goldsborough as Chief Science and Technology Officer (CSTO).
The Centers for Disease Control and Prevention (CDC) awarded ATCC a $1.1 million, five-year contract to support the National Health and Nutrition Examination Survey (NHANES) program.
ATCC announces the release of three cell lines for investigating biological processes associated with a key Parkinson’s disease genetic target. The production and authentication of these tools is funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
ATCC announces two executive leadership appointments to help drive new business growth and build ATCC’s brand in a dynamic and competitive environment.
ATCC is partnering with the research, academic, and public health communities to respond to the growing Zika virus crisis.
ATCC announces that the ATCC Standards Development Organization (SDO) completed and published the consensus standard: Species-Level Identification of Animal Cells through Mitochondrial Cytochrome c Oxidase Subunit 1 (CO1) DNA Barcodes (ANSI/ASN-0003-2015) for interspecies cell line identity based on sequence technology.
ATCC is poised to assist the medical and life science researchers that are working to address the evolving concerns around Zika Virus infection.
ATCC announces that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard.